Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Graziano

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
The Pharmacogenomics Journal|December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineG Visani, F Loscocco, A Ruzzo, et al.
Frontiers in Surgery|July 15, 2022
Women in Neurosurgery: Historical Path to Self-Segregation and Proposal for an Integrated FutureD Garozzo, R Rispoli, F Graziano, et al.
Science Advances|February 26, 2019
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapyMegan M Tu, Francis Y F Lee, Robert T Jones, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
The Pharmacogenomics Journal|December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineG Visani, F Loscocco, A Ruzzo, et al.
Frontiers in Surgery|July 15, 2022
Women in Neurosurgery: Historical Path to Self-Segregation and Proposal for an Integrated FutureD Garozzo, R Rispoli, F Graziano, et al.
Science Advances|February 26, 2019
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapyMegan M Tu, Francis Y F Lee, Robert T Jones, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Pageof 17